Pharmacoeconomic features of increased costs of direct-acting and oral anticoagulants in a multidisciplinary hospital in 2019–2021

Abstract

The purpose of the work is to analyze the costs of direct-acting anticoagulants and oral anticoagulants from the total cost of medicines by years in a multidisciplinary hospital, as well as to calculate the cost of a daily prophylactic dose of drugs on the example of apixaban and sodium heparin